Ceva: Ceva receives EU marketing authorization for Cirbloc M Hyo
The new vaccine is based on the PCV2d genotype, the most circulating one in the field and on the Mycoplasma hyopneumoniae (M. hyo) strain BA 2940.
Read full article »
Ceva is a France-based veterinary pharmaceutical company that researches and develops products such as vaccines and antibiotics for pets.
Read more